Business
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the “Board”) has determined to adopt a limited-duration stockholder rights plan (the “Rights Plan”), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company’
About this update from Neuphoria Therapeutics Inc.
[{"type":"image","alt":"Neuphoria Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Neuphoria Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":134,"url":"https://media.zenfs.com/en/globenewswire.com/ebf32c6b9691a7e95d55714797b59361"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mnUSgCG0WTU8RlTRZzCzeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebf32c6b9691a7e95d55714797b59361","width":300,"height":134}},"lazy":false},{"type":"text","content":"BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the “Board”) has determined to adopt a limited-duration stockholder rights plan (the “Rights Plan”), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company’s publicly traded common stock by certain investors.","length":557,"tagName":"p"},{"type":"text","content":"The Rights Plan is intended to protect the interests of the Company and its stockholders, help ensure that all interested parties have the opportunity to participate fairly in any strategic review process and to provide the Board time to make informed decisions. The Rights Plan will reduce the likelihood that any entity, person or group gains control of Neuphoria through open-market accumulation without paying all stockholders an appropriate control premium.","length":462,"tagName":"p"},{"type":"text","content":"It is important to note that the Rights Plan does not preclude the Board from engaging with parties or considering proposals or other strategic alternatives that it believes recognize the full value of the Company and are in the best interests of Neuphoria and all stockholders.","length":278,"tagName":"p"},{"type":"text","content":"The Rights Plan, which is similar to other plans adopted by publicly held companies, does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of the Board to redeem the rights.","length":213,"tagName":"p"},{"type":"text","content":"In connection with the adoption of the Rights Plan, the Board declared a dividend of one...